Ocular inflammation stimulated by the immunomodulator AS101 [ammonium trichloro(dioxyethelene-O-O') tellurate]. 1994

K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892.

The purpose of this study was to investigate the effect of a novel immunomodulator, AS101 [ammonium trichloro(dioxyethelene-O-O') tellurate], in the eye. Lewis rats were injected intravitreally with AS101 at a concentration of 13 micrograms/ml in one eye and BSS in the contralateral eye. Control animals were injected with BSS into the central vitreous of both eyes. Ocular inflammation was evaluated at 20 hours by histology, immunopathology, and by cell count, protein and cytokine measurement in the aqueous humor. At 20 hours, eyes injected with AS101 developed iridocyclitis and mild vitritis versus minimal inflammation and/or protein in contralateral eyes or eyes of control animals (p = 0.0121). The inflammatory infiltrate was mixed in character. Major Histocompatibility Complex (MHC) class II antigens and intercellular adhesion molecules (ICAM-1) were expressed in the anterior segment of eyes injected with AS101. In the aqueous humor of these eyes there were significant quantities of inflammatory cells, protein (mean +/- SEM = 11.2 +/- 2.3 mg/ml) and the cytokine interleukin 6 (IL-6) (450 units/ml) compared with contralateral eyes (p = 0.0005 for inflammatory cells; protein, mean +/- SEM = 1.6 +/- 0.17 mg/ml; IL-6 = 12 units/ml) and both eyes of control animals injected with BSS (p = 0.8955 for inflammatory cells; protein, OD = 1.5 mg/ml, OS = 0.7 mg/ml; IL-6, OD = 8 units/ml, OS = 13 units/ml). AS101 has a local inflammatory effect in the eye. This compound may activate ocular inflammation by releasing cytokines such as IL-6.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D005030 Ethylenes Derivatives of ethylene, a simple organic gas of biological origin with many industrial and biological use.
D005128 Eye Diseases Diseases affecting the eye. Eye Disorders,Eye Disease,Eye Disorder
D005260 Female Females
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000869 Anterior Eye Segment The front third of the eyeball that includes the structures between the front surface of the cornea and the front of the VITREOUS BODY. Anterior Eye Segments,Eye Segment, Anterior,Eye Segments, Anterior,Segment, Anterior Eye,Segments, Anterior Eye
D000949 Histocompatibility Antigens Class II Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen. Antigens, Immune Response,Class II Antigens,Class II Histocompatibility Antigen,Class II Major Histocompatibility Antigen,Ia Antigens,Ia-Like Antigen,Ia-Like Antigens,Immune Response Antigens,Immune-Associated Antigens,Immune-Response-Associated Antigens,MHC Class II Molecule,MHC II Peptide,Class II Antigen,Class II Histocompatibility Antigens,Class II MHC Proteins,Class II Major Histocompatibility Antigens,Class II Major Histocompatibility Molecules,I-A Antigen,I-A-Antigen,IA Antigen,MHC Class II Molecules,MHC II Peptides,MHC-II Molecules,Antigen, Class II,Antigen, I-A,Antigen, IA,Antigen, Ia-Like,Antigens, Class II,Antigens, Ia,Antigens, Ia-Like,Antigens, Immune-Associated,Antigens, Immune-Response-Associated,I A Antigen,II Peptide, MHC,Ia Like Antigen,Ia Like Antigens,Immune Associated Antigens,Immune Response Associated Antigens,MHC II Molecules,Molecules, MHC-II,Peptide, MHC II,Peptides, MHC II

Related Publications

K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
February 2014, International journal of molecular sciences,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
March 2004, Cancer research,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
July 2015, International journal of molecular medicine,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
March 1995, Blood,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
October 1998, Journal of immunology (Baltimore, Md. : 1950),
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
April 1993, Cancer research,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
December 1993, Cancer research,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
September 2017, Behavioural pharmacology,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
June 2007, The FEBS journal,
K Dastgheib, and N Hikita, and B Sredni, and M Albeck, and D Sredni, and R B Nussenblatt, and C C Chan
January 1993, Experimental hematology,
Copied contents to your clipboard!